Management of Hyperprolactinemia

First-Line Treatment

The American College of Endocrinology recommends cabergoline as the first-line treatment for hyperprolactinemia due to its superior efficacy in normalizing prolactin levels (83% vs 59% for bromocriptine) and better tolerability profile (52% vs 72% adverse events compared to bromocriptine) 1, 2
Initial dosing strategy for cabergoline is 0.25 mg twice weekly for the first 4 weeks, with gradual titration to a standard maintenance dose of up to 2 mg/week for microprolactinomas (<13.5 mm) 1, 2

The Endocrine Society recommends baseline echocardiography before initiating cabergoline treatment for all patients 3, 1
For doses >2 mg/week, annual echocardiography with cardiac auscultation is mandatory due to increased risk of cardiac valvulopathy 3, 1

Normalization of prolactin levels is expected in 60-70% of patients treated with cabergoline 1
Tumor shrinkage is expected in 80-88% of cases treated with cabergoline 1

The European Society of Endocrinology recommends considering gradual cabergoline dose reduction if prolactin levels have been normalized for at least 2 years on medical therapy and there is no visible residual prolactinoma on MRI 3, 1
Relapse rates after discontinuation vary from 26-89%, with most recurrences occurring within the first 2 years 1

The American Association of Clinical Endocrinologists recommends considering transsphenoidal surgery after multidisciplinary discussion when the patient is unable to tolerate or is resistant to high-dose cabergoline 1
Surgery achieves normalization of prolactin in approximately 80% of microprolactinomas and 60% of macroprolactinomas, especially in high-volume surgical centers 3

The Pediatric Endocrine Society recommends offering echocardiogram at the start of treatment with a dopamine agonist in children and young people 3
The often more aggressive nature of prolactinomas in the pediatric age group requires longer treatment durations and higher cumulative doses than adults 3